Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neeraj Sachdeva

Gastroenterology Raleigh, NC Medical Doctor

NPI 1164562005 CMS profile 143217

2601 Lake Dr, Ste 201, Raleigh, NC 27607

Open in the dashboard

General payments

$19,007

446 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neeraj Sachdeva of Raleigh, NC is reported in the CMS Open Payments database as having received $19,007 across 446 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,281 64
2024 General $1,659 82
2023 General $8,597 82
2022 General $4,866 78
2021 General $1,052 57
2020 General $299 16
2019 General $1,252 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neeraj Sachdeva
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Neeraj Sachdeva were reported at $1,281. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Neeraj Sachdeva Gastroenterology median Middle half National median
2019 $1,252 $417 $126–$1,100 $163
2020 $299 $224 $74–$624 $114
2021 $1,052 $352 $106–$1,054 $132
2022 $4,866 $448 $129–$1,270 $149
2023 $8,597 $533 $150–$1,390 $160
2024 $1,659 $605 $160–$1,606 $164
2025 $1,281 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $11,059 35 payments
  2. AbbVie, Inc. $2,083 117 payments
  3. Pfizer Inc. $808 47 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $722 36 payments
  5. Intercept Pharmaceuticals, Inc. $547 26 payments
  6. Celgene Corporation $484 26 payments
  7. Janssen Biotech, Inc. $321 18 payments
  8. Ferring Pharmaceuticals Inc. $310 15 payments
  9. Lilly USA, LLC $298 13 payments
  10. Merck Sharp & Dohme Corporation $280 17 payments
  11. Other $2,096 96 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,500 3 payments
  2. Food and Beverage $8,416 438 payments
  3. Education $91 5 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $10,904 25 payments
  2. TRULANCE $3,636 9 payments
  3. RINVOQ $835 48 payments
  4. XELJANZ $636 37 payments
  5. ZEPOSIA $484 26 payments
  6. LINZESS $442 27 payments
  7. OCALIVA $439 20 payments
  8. SKYRIZI $421 24 payments
  9. ENTYVIO $376 16 payments
  10. STELARA $369 21 payments
  11. Other $5,220 283 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

673

Median for Gastroenterology: 569

Drug cost

$70,033

Median for Gastroenterology: $104,976

Branded share of claims

44.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 16 $40,584
Linzess Linaclotide Brand 17 $19,930
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 143 $3,106
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 30 $2,195
Omeprazole Generic 90 $1,579
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 55 $903
Mercaptopurine Generic 14 $638
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 39 $581
Pantoprazole Sodium Generic 21 $279
Ondansetron Hcl Generic 169 $146

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$523,512

Of which drugs: $268,358

Medicare patients

1,812

Average age 72

Services billed

21,346

954 women, 858 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 39%
Diabetes 25%
Depression 18%
Ischemic heart disease 17%
Chronic kidney disease 17%
Cancer 16%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 14 9,000 $156,468
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 15 1,220 $30,432

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $192
$192 — —
VELSIPITY
  • PFIZER INC. $138
$138 — —
ZEPOSIA
  • Celgene Corporation $120
$120 — —
OMVOH
  • Lilly USA, LLC $110
$110 — —
SKYRIZI
  • AbbVie, Inc. $105
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record